Cold sore virus modified to fight kidney cancer in new trial
NCT ID NCT07218692
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if the combination is safe and can shrink tumors. Participants will receive the virus injection and oral tivozanib, along with biopsies and imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP2 (a modified herpes simplex virus) and tivozanib hydrochloride
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced kidney cancer that has stopped responding to immunotherapy.
What could go wrong
This is a small, early-phase trial (35 participants) testing safety and effectiveness. The virus-based therapy may cause side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Contact Email: •••••@•••••
Contact